Harmony Biosciences Holdings Inc

HRMY is in a Stage 2 corrective reset within its broader uptrend, holding above the rising 50 DMA but with short EMAs flattened and offering resistance. Medium-term bias remains bullish on the Advancing phase and structural support, while short-term timing is unfavorable. Patience is warranted for a pullback into the 9/21 EMAs or 50 DMA to confirm support before engaging.

• ↑Q1 2026 revenue $215.4M (+17% YoY) with full-year guidance >$1B demonstrates robust growth.
• ↑Cash and equivalents of $870.5M support late-stage trials and M&A optionality.
• ↓Operating expenses surged to $133.6M, dragging Q1 net income to $32.5M.